Vaccine effectiveness against severe COVID-19 outcomes within the French overseas territories: A cohort study of 2-doses vaccinated individuals matched to unvaccinated ones followed up until September 2021 and based on the National Health Data System
暂无分享,去创建一个
M. Zureik | R. Dray-Spira | J. Deloumeaux | C. Joachim | E. Sylvestre | A. Weill | L. Semenzato | B. Baricault | J. Botton
[1] M. Zureik,et al. Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations , 2022, JAMA network open.
[2] R. Irizarry,et al. Effectiveness estimates of three COVID-19 vaccines based on observational data from Puerto Rico , 2022, The Lancet Regional Health - Americas.
[3] M. Bertrand,et al. Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines , 2021, Vaccine.
[4] O. A. Ogun,et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study , 2021, The Lancet.
[5] William F. Fadel,et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings , 2021, The New England journal of medicine.
[6] M. Zureik,et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people , 2021, The Lancet Regional Health - Europe.
[7] L. Abu-Raddad,et al. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.
[8] D. Swerdlow,et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data , 2021, The Lancet.
[9] Hannah Ritchie,et al. A global database of COVID-19 vaccinations , 2021, Nature Human Behaviour.
[10] Nguyen H. Tran,et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.
[11] Nguyen H. Tran,et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. , 2020, Lancet.
[12] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[13] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[14] A. Fagot-Campagna,et al. [Health status of populations living in French overseas territories in 2012, compared with metropolitan France: An analysis of the national health insurance database]. , 2016, Revue d'epidemiologie et de sante publique.